United States · Bill · S
S. 1169 (116th)
Ensuring Timely Access to Generics Act of 2019
Introduced
11 April 2019
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
5 December 2025
Summary
Ensuring Timely Access to Generics Act of 2019 This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application. The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission. The FDA may establish a timeline for submitting petitions.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate (text)
Introduced in Senate · EN · 11 April 2019
Introduced in Senate (PDF)
Introduced in Senate · EN · 11 April 2019
Introduced in Senate
summary · EN · 11 April 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/senate-bill/1169
- Open data entity: https://api.congress.gov/v3/bill/116/s/1169